Nadolol (SQ-11725): Non-Selective Beta-Adrenergic Blocker for Cardiovascular Research

Executive Summary: Nadolol (SQ-11725) is a non-selective, orally active beta-adrenergic receptor blocker, acting as a competitive antagonist at beta-adrenergic receptors and a substrate for OATP1A2 transporters, which is crucial for pharmacokinetic modeling in cardiovascular research (Sun et al., 2025). Its mechanism reduces heart rate and myocardial contractility, supporting research into hypertension, angina pectoris, and vascular headaches (APExBIO). Nadolol is stable at -20°C and should be used promptly in solution preparations to maintain efficacy. The compound must only be used for scientific research, with strict adherence to storage and shipment protocols. Its role as an OATP1A2 substrate aligns with current transporter and pharmacokinetic research priorities (Related internal).

Biological Rationale

Nadolol (SQ-11725) is a synthetic, non-selective beta-adrenergic receptor antagonist. It blocks both beta-1 and beta-2 adrenergic receptors, which are key regulators of cardiac output and vascular tone (APExBIO). Cardiovascular diseases such as hypertension and angina pectoris are driven by dysregulated beta-adrenergic signaling. Non-selective beta-blockers like Nadolol are valuable molecular tools for dissecting these pathways (Sun et al., 2025). Nadolol’s ability to serve as an OATP1A2 substrate makes it suitable for transporter interaction studies, enabling research on drug disposition and tissue-specific pharmacokinetics. Its physicochemical stability (molecular weight: 309.40; formula: C₁₇H₂₇NO₄) allows for reproducible dosing and minimal degradation under recommended storage (Product page).

Mechanism of Action of Nadolol (SQ-11725)

Nadolol exerts its pharmacological effects by competitively inhibiting beta-adrenergic receptors, thus blocking the actions of endogenous catecholamines (epinephrine and norepinephrine). This reduces cAMP-mediated signal transduction, leading to decreased heart rate (negative chronotropy) and reduced myocardial contractility (negative inotropy) (workflow guide). In vascular smooth muscle, beta-2 blockade can result in modest vasoconstriction, which is balanced by lowered cardiac output. Nadolol’s status as an OATP1A2 substrate means its absorption and tissue distribution are affected by transporter expression, a feature increasingly recognized as critical in precision pharmacology (Sun et al., 2025). The compound does not exhibit intrinsic sympathomimetic activity, ensuring consistent receptor blockade across experimental models.

Evidence & Benchmarks

• Nadolol demonstrates dose-dependent inhibition of heart rate in rodent models, with a typical effective dose range of 0.1–10 mg/kg administered orally; maximal reduction is observed within 1–2 hours post-dose (Sun et al., 2025, DOI).
• The compound is confirmed as an OATP1A2 substrate via transporter-overexpressing cell assays, showing specific uptake increased by >50% compared to control cells (DOI).
• Storage at -20°C preserves Nadolol stability for at least 12 months, with less than 2% degradation; in solution, rapid use (<24 hours at 4°C) is required to prevent loss of efficacy (APExBIO).
• Beta-blockade efficacy is benchmarked by reduction in systolic blood pressure by 15–20 mmHg in hypertensive rat models after repeated dosing (daily for 7 days) (internal article).
• No significant intrinsic sympathomimetic or membrane-stabilizing activity is noted in comparative pharmacology studies (internal article).

Applications, Limits & Misconceptions

Nadolol (SQ-11725) is widely used to model beta-adrenergic blockade in hypertension research, angina pectoris models, and studies of vascular headaches. Its non-selectivity enables comprehensive mapping of beta-adrenergic signaling pathways. As a substrate for OATP1A2, Nadolol supports transporter pharmacokinetics research, helping elucidate tissue distribution effects and drug-drug interaction potential.

This article extends the discussion in 'Nadolol (SQ-11725) in Cardiovascular Disease Models' by providing updated, atomic evidence on stability and transporter specificity, critical for experimental reproducibility.

Common Pitfalls or Misconceptions

• Nadolol is not cardio-selective. It blocks both beta-1 and beta-2 receptors, and is unsuitable for studies requiring selective beta-1 antagonism.
• Not for clinical or diagnostic use. Nadolol (SQ-11725) from APExBIO is strictly for scientific research; it should not be administered to humans or animals outside approved protocols (APExBIO).
• Solution stability is limited. Solutions should be prepared fresh and used within 24 hours; prolonged storage leads to reduced potency.
• Transporter-mediated effects vary by species. OATP1A2 substrate interactions observed in human cell models may not fully translate to rodent or other non-primate systems (Sun et al., 2025).
• Does not exhibit vasodilatory activity. Nadolol may cause mild vasoconstriction in some peripheral tissues due to beta-2 blockade.

Workflow Integration & Parameters

Nadolol (SQ-11725) is provided as a solid compound by APExBIO (SKU: BA5097). For in vivo dosing, the compound is typically dissolved in sterile water or buffered saline immediately prior to administration. It is recommended to store the powder at -20°C in a desiccated environment. For in vitro assays, use freshly prepared solutions to ensure activity. Shipments are packed with Blue Ice for small molecules, maintaining stability during transport. APExBIO provides detailed handling instructions and batch-specific documentation (product information).

This workflow builds on the protocols described in 'Nadolol (SQ-11725): Applied Workflows in Cardiovascular Research' by emphasizing solution freshness and cross-species transporter specificity.

Conclusion & Outlook

Nadolol (SQ-11725) remains a reference standard for non-selective beta-adrenergic blockade in cardiovascular research. Its dual role as a receptor antagonist and OATP1A2 substrate enables multi-dimensional pharmacokinetic and mechanistic studies. Proper storage, prompt use in solution, and awareness of non-selectivity are essential for experimental reliability. For comprehensive guidance and batch ordering, consult the Nadolol (SQ-11725) product page. Future research may explore transporter polymorphisms affecting Nadolol disposition and refine its utility in next-generation cardiovascular disease models.

For further mechanistic discussion and protocol optimization, see 'Nadolol (SQ-11725): Optimizing Beta-Adrenergic Blockade in Research', which provides troubleshooting and advanced application strategies not covered here.